Ocular Surface Disease

Phentolamine ophthalmic solution 0.75% is a preservative-free, stable eye drop, which blocks the α1 receptor within the iris dilator muscle without affecting the ciliary muscle.

OKYO Pharma announced the acceptance of OK-101 as an investigational new drug following clinical studies investigating the candidate in patients with neuropathic corneal pain, the first to do so.

Harrow’s Vevye is the first and only cyclosporine-based product approved for the treatment of both signs and symptoms of dry eye disease.

According to OKYO Pharma, the first-in-human, randomized, double-masked, placebo-controlled trial of OK-101 “established a clear and informed path for further development in Phase 3 registration trials.”

Regarding both the amount and speed of symptom improvement, patients were more satisfied with the insert compared with the topical steroid, but there was no statistically significant difference vs the topical antihistamine in terms of satisfaction.

The revision is in response to multiple recalls for eye drops and instances of consumer injury and death in 2023.

Dry eye disease incidence rates vary markedly depending on the eye care practice.

Vezocolmitide is the first drug candidate based on PolyCol, Stuart Therapeutics' patented synthesized polypeptide collagen mimetic peptide platform.

Much has changed in the study of keratoconus over the years.

A look back at some of the biggest stories in ophthalmology in 2023.

2 cases illustrate the importance of ocular surface optimization.

Using the NEI protocol for addressing corneal staining, researchers used 5 microliters of 2%, non preserved fluorescein and then evaluated corneal staining.

This is just one of many times the FDA has issued a warning to companies for the sale of unapproved ophthalmic products in 2023.

For patients with keratoconus-related inflammation, an intracanalicular steroid insert rivals the effectiveness of eye drops while boosting adherence.

Patients who have signs or symptoms of an eye infection after using these products should talk to their health care provider or seek medical care immediately.

The FDA recalled 26 eye drops due to risk of infection and possible vision loss.

Here’s why formulation matters.

Collaboration between ophthalmologists, optometrists can boost early detection.

Tracy Doll, OD, FAAO, shares an overview of her anterior segment symposium presented during the 2023 AAOpt annual meeting.

Private practice eye care providers’ ability to immediately administer antibiotic eye drops or have them overnighted to the patient is a giant step forward for practice and patient.

Therapies and technologies to treat allergic conjunctivitis are rapidly changing.

Hear what is new in the world of ocular surface disease, and what's coming down the pipeline.

Results of the BRIO-I study, the first of 2 phase 3 clinical trials of Brimochol PF, a topical, fixed-dose combination for the treatment of presbyopia, have recently been released.

Ben Bergo, CEO of Visus, shares data from the company's pivotal phase 3 BRIO-1 trial, as well as answers questions about Brimochol PF.